CXCL8 and cancer: In fact, HuMax-IL-8 (BMS-986253), a novel fully human monoclonal anti-IL-8 antibody has recently been introduced in different phase I trials testing its anti-cancer potential [NCT02536469, NCT03689699] (Bilusic et al., 2019).